In a landmark decision that has been welcomed by medical professionals and patient advocacy groups worldwide, Polycystic Ovary Syndrome (PCOS) has been officially renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change, announced by the International Federation of Gynecology and Obstetrics (FIGO) on May 13, 2026, aims to better reflect the underlying metabolic and endocrine nature of the condition, moving away from the misleading emphasis on ovarian cysts.
Why the Name Change Matters
The term "polycystic ovaries" has long been criticized for focusing on a single symptom that not all patients exhibit. Many women with PCOS do not have ovarian cysts, while others with cysts do not have the syndrome. This has led to confusion, misdiagnosis, and stigma. The new name, PMOS, highlights the condition's systemic metabolic and hormonal imbalances, which include insulin resistance, hyperandrogenism, and chronic inflammation.
Dr. Sarah Mitchell, a leading endocrinologist at Johns Hopkins University, stated, "This renaming is a crucial step toward destigmatizing the condition and improving patient care. It shifts the focus from a purely reproductive disorder to a comprehensive metabolic syndrome that affects multiple body systems."
Impact on Diagnosis and Treatment
The renaming is expected to have significant implications for diagnosis and treatment. With a more accurate name, healthcare providers may be more likely to screen for metabolic complications such as type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. Treatment protocols are also likely to evolve, emphasizing lifestyle interventions and medications that target insulin resistance and inflammation, rather than solely focusing on ovarian symptoms.
Patient Advocacy Groups React
Patient advocacy groups have expressed strong support for the change. The PCOS Awareness Association called it "a victory for millions of women who have felt misunderstood and misdiagnosed." The association hopes that the new name will encourage more research funding and public awareness campaigns.
Global Adoption and Next Steps
FIGO has urged all medical bodies, journals, and health organizations to adopt the new terminology immediately. The World Health Organization (WHO) is expected to update its classification in the next revision of the International Classification of Diseases (ICD). Medical textbooks and educational materials will also be revised to reflect the change.
While the name change is being celebrated, experts caution that it is just one part of a larger effort to improve care for women with PMOS. Continued research into the underlying causes, better diagnostic criteria, and personalized treatment approaches remain essential.
The renaming of PCOS to PMOS marks a new chapter in women's health, one that promises more accurate diagnosis, reduced stigma, and better outcomes for millions of women worldwide.
